Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis

Abstract

The tumor suppressor protein prostate apoptosis response-4 (Par-4), which is secreted by normal cells, selectively induces apoptosis in cancer cells. We identified a 3-arylquinoline derivative, designated Arylquin 1, as a potent Par-4 secretagogue in cell cultures and mice. Mechanistically, Arylquin 1 binds vimentin, displaces Par-4 from vimentin for secretion and triggers the efficient paracrine apoptosis of diverse cancer cells. Thus, targeting vimentin with Par-4 secretagogues efficiently induces paracrine apoptosis of tumor cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Arylquin 1 displaces Par-4 bound to vimentin to induce Par-4 secretion.
Figure 2: Arylquin 1 induces paracrine apoptosis in cancer cells.

Similar content being viewed by others

References

  1. Siegel, R., Naishadham, D. & Jemal, A. CA Cancer J. Clin. 62, 10–29 (2012).

    Article  Google Scholar 

  2. Viallet, J. & Minna, J.D. Am. J. Respir. Cell Mol. Biol. 2, 225–232 (1990).

    Article  CAS  Google Scholar 

  3. Luo, S.Y. & Lam, D.C.L. Transl. Respir. Med. 1, 6–8 (2013).

    Article  Google Scholar 

  4. Chen, F., Wang, W. & El-Deiry, W.S. Biochem. Pharmacol. 80, 724–730 (2010).

    Article  CAS  Google Scholar 

  5. Burikhanov, R. et al. Cell 138, 377–388 (2009).

    Article  CAS  Google Scholar 

  6. Burikhanov, R. et al. Cancer Res. 73, 1011–1019 (2013).

    Article  CAS  Google Scholar 

  7. Hebbar, N., Wang, C. & Rangnekar, V.M. J. Cell. Physiol. 227, 3715–3721 (2012).

    Article  CAS  Google Scholar 

  8. Shrestha-Bhattarai, T., Hebbar, N. & Rangnekar, V.M. Cancer Cell 24, 3–5 (2013).

    Article  CAS  Google Scholar 

  9. Alvarez, J.V. et al. Cancer Cell 24, 30–44 (2013).

    Article  CAS  Google Scholar 

  10. Vassilev, L.T. et al. Science 303, 844–848 (2004).

    Article  CAS  Google Scholar 

  11. Burikhanov, R. et al. Cell Reports 6, 271–277 (2014).

    Article  CAS  Google Scholar 

  12. Satelli, A. & Shulin, L. Cell. Mol. Life Sci. 68, 3033–3046 (2011).

    Article  CAS  Google Scholar 

  13. Eckes, B. et al. J. Cell Sci. 113, 2455–2462 (2000).

    CAS  PubMed  Google Scholar 

  14. Gillard, B.K., Harrell, R.G. & Marcus, D.M. Glycobiology 6, 33–42 (1996).

    Article  CAS  Google Scholar 

  15. Amberg, W. et al. World Intellectual Property Organization, PCT WO2007022946 A1 20070301 (2007).

  16. Lecher, H.Z., Greenwood, R.A., Whitehouse, K.C. & Chao, T.H. J. Am. Chem. Soc. 78, 5018–5022 (1956).

    Article  CAS  Google Scholar 

  17. Zhang, W. et al. ACS Chem. Biol. 8, 796–803 (2013).

    Article  CAS  Google Scholar 

  18. Goswami, A. et al. Cancer Res. 68, 6190–6198 (2008).

    Article  CAS  Google Scholar 

  19. Bargagna-Mohan, P. et al. J. Biol. Chem. 285, 7657–7669 (2010).

    Article  CAS  Google Scholar 

  20. Bargagna-Mohan, P. et al. Chem. Biol. 14, 623–634 (2007).

    Article  CAS  Google Scholar 

  21. Hamza, A. et al. J. Chem. Inf. Model. 54, 1166–1173 (2014).

    Article  CAS  Google Scholar 

  22. Hamza, A. & Zhan, C.-G. J. Phys. Chem. B 113, 2896–2908 (2009).

    Article  CAS  Google Scholar 

  23. Zhang, T. et al. Mol. Cancer Ther. 7, 162–170 (2008).

    Article  CAS  Google Scholar 

  24. Case, D.A. et al. AMBER 12. University of California, San Fransisco, (2012).

  25. Berendsen, H.J.C., Postma, J.P.M., Vangunsteren, W.F., Dinola, A. & Haak, J.R. J. Chem. Phys. 81, 3684–3690 (1984).

    Article  CAS  Google Scholar 

  26. Ryckaert, J.P., Ciccotti, G. & Berendsen, H.J.C. J. Comput. Phys. 23, 327–341 (1977).

    Article  CAS  Google Scholar 

  27. Darden, T., York, D. & Pedersen, L. J. Chem. Phys. 98, 10089–10092 (1993).

    Article  CAS  Google Scholar 

  28. Hamza, A. et al. J. Phys. Chem. B 114, 5605–5616 (2010).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by National Center for Research Resources through 'COBRE Center for Biomedical Research Excellence' grant P20 RR020171 (to L. Hersh, who is the principal investigator of the study on which D.S.W. is core director), NIH–National Cancer Institute grants R01 CA60872 and R21 CA179283 (to V.M.R.) and University of Kentucky Center for Clinical and Translational Science Drug Discovery Pilot grant (to V.M.R., D.S.W. and C.L.).

Author information

Authors and Affiliations

Authors

Contributions

R.B. contributed to experimental biological studies; V.M.S. contributed to arylquin organic syntheses; N.H. contributed to experimental biological studies; W.Z. contributed to experimental biological studies; W.J.L. contributed to NMR studies characterizing arylquins; A.H. contributed to computational studies; C.-G.Z. contributed to computational studies; D.S.W. contributed to the design of arylquin syntheses; C.L. contributed to biological studies of biotinylated arylquin; and V.M.R. contributed to the design of Par-4 biological studies.

Corresponding author

Correspondence to Vivek M Rangnekar.

Ethics declarations

Competing interests

V.M.R., D.S.W. and C.L. hold 30% equity each in a limited liability corporation, Curonc LLC, founded for the purpose of advancing translational research involving arylquins, and the University of Kentucky has filed a preliminary patent application for these compounds in which these authors are co-inventors.

Supplementary information

Supplementary Text and Figures

Supplementary Results, Supplementary Figures 1–27, Supplementary Table 1 and Supplementary Note. (PDF 2944 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Burikhanov, R., Sviripa, V., Hebbar, N. et al. Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis. Nat Chem Biol 10, 924–926 (2014). https://doi.org/10.1038/nchembio.1631

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nchembio.1631

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer